National Taiwan University Hospital

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Friday, April 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

Volition Presents Three Cancer Detection Abstracts at ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Diagnosis, Lung cancer, NYSE, Biomarker, Plasma, University, Volition, Cancer, Nucleosome, National Taiwan University Hospital, ESMO, Oncology, Université de Namur, Research institute, Clinical Trial Service Unit, Nucleic acid thermodynamics, European Society for Medical Oncology, CTCF, Glioblastoma, Malignancy, Poster, Nursing

HENDERSON, Nev., Oct. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting three scientific abstracts at ESMO 2023, the annual congress of the European Society for Medical Oncology.

Key Points: 
  • HENDERSON, Nev., Oct. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting three scientific abstracts at ESMO 2023, the annual congress of the European Society for Medical Oncology.
  • Dr. Jake Micallef, Chief Scientific Officer at Volition, said: "We are delighted to be attending ESMO 2023 and have the opportunity to share exciting new data in lung cancer and glioblastoma, and introduce what we believe to be an entirely new method for the detection of cancer."
  • On Saturday 21st October, Dr. Dorian Pamart, Head of Technology and Service Unit at Volition, will present a poster (205P) titled 'A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer'.
  • The study was undertaken by Volition and the National Taiwan University Hospital and is part of a longer-term research collaboration.

Taiwan Launches National Lung Cancer Early Detection Program Detects 85 Percent of Lung Cancer Cases at Early Phase

Retrieved on: 
Monday, September 11, 2023
ACR, National Taiwan University Hospital, Parent, Health, International Association, Lung cancer, Woman, Risk, History, Lung, Doctor of Philosophy, Adrian Dixon, Sibling, MD, Guideline, Case management, Mortality, Ageing, Diagnosis, American College, Conference, Uranium mining, Antibiotics, Life insurance, Medical imaging

SINGAPORE, Sept. 11, 2023 /PRNewswire-PRWeb/ -- The Taiwan National Lung Cancer Early Detection Program detected 85 percent of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively. The results of the program were presented by Pan-Chyr Yang, MD, PhD from the National Taiwan University Hospital, at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer today in Singapore.

Key Points: 
  • The Taiwan National Lung Cancer Early Detection Program detected 85 percent of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively.
  • SINGAPORE, Sept. 11, 2023 /PRNewswire-PRWeb/ -- The Taiwan National Lung Cancer Early Detection Program detected 85 percent of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively.
  • "The Taiwan National Lung Cancer Early Detection Program is a significant step forward in the fight against lung cancer, offering hope for saving lives through early detection and improved treatment outcomes."
  • To combat lung cancer and improve survival rates, Taiwan has taken a groundbreaking step by introducing the "Taiwan National Lung Cancer Early Detection Program."

Taiwan Firm AHEAD Medicine Disrupting cell analysis with AI to help accelerate disease diagnostics and cell therapy worldwide

Retrieved on: 
Friday, July 29, 2022
Ministry of Science and Technology (India), Time, University of California, Berkeley, Physician, Human, Flow cytometry, Data science, Medicine, CEO, Drug discovery, MOST, Software, Health, National Tsing Hua University, National Taiwan University Hospital, Patent, STEM, Safety, Multimedia, UC, Ministry, Intelligence, Hospital, RUO, Wang, Lymphoma, Pharmaceutical industry, Technology, Science

TAIPEI, July 28, 2022 /PRNewswire/ -- AHEAD Medicine, a UC Berkeley SkyDeck-backed company has launched a new AI-enabled cell immuno-profiling analysis platform. The platform unlocks the cell-level data critical to vaccine, therapeutic research & development, patient diagnosis, and the safety of next generation treatments like cell therapy, the company will be showcasing its technology at US bio 2022.

Key Points: 
  • AHEAD Medicine's AI platform removes bottlenecks in drug discovery, clinical trials, and patient treatment, increasing speed, accuracy, and reproducibility.
  • TAIPEI, July 28,2022 /PRNewswire/ -- AHEAD Medicine, a UC Berkeley SkyDeck-backed company has launched a new AI-enabled cell immuno-profiling analysis platform.
  • Andrea Wang, CEO and co-founder of AHEAD Medicine, a cancer survivor with graduate experience in cancer research and data science, has always had a keen interest in applying AI to medicine.
  • AHEAD Medicine is currently expanding globally, with a new US Headquarters opened in California, and it's first RUO product available for acute leukemia and lymphoma.

Launch of World-first Expert Bone Health Resource

Retrieved on: 
Monday, May 23, 2022
Department, Risk, Health, Disease, Population, Bone health, National Taiwan University Hospital, Senior Consultant, APCO, Singapore General Hospital, Consultant, Interview, Projection, NTUH, Probability, Sarcopenia, Fracture, Hip, IOF, Director, International Osteoporosis Foundation, Development, Diagnosis, Dietary supplement, Dentistry, Endocrinology, Osteoporosis

This is due to the region's rapidly ageing population, mounting urbanisation, and subsequent increase in sedentary lifestyles.

Key Points: 
  • This is due to the region's rapidly ageing population, mounting urbanisation, and subsequent increase in sedentary lifestyles.
  • (2)
    In an effort to stem this health crisis, the Asia Pacific Consortium on Osteoporosis (APCO) will launch a Bone Health QI Tool Kit for healthcare professionals Tuesday, May 24, 2022, to promote quality improvement of osteoporosis care.
  • This world-first tool kit, encompassing multiple components in the screening, diagnosis, and management of osteoporosis, will help to promote multi-sector healthcare professional engagement and cooperation, to address this looming healthcare catastrophe.
  • Cheung, C.-L., et al., An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study.

StemCyte, a leading regenerative cell therapy company, has submitted its application for a biologics license (BLA) for its allogeneic umbilical cord hematopoietic progenitor cell product "HPC-Cord Blood", to the US FDA

Retrieved on: 
Tuesday, March 22, 2022
BLA, 2009 Davis Cup, Time-invariant system, Stroke, Ronald Reagan UCLA Medical Center, Duke University Hospital, Transplant, Multimedia, Cerebral palsy, Lists of diseases, Disorder, National Taiwan University Hospital, FDA, Biologics license application, Patient, Medical device, Pharmaceutical industry

BALDWIN PARK, Calif., March 22, 2022 /PRNewswire/ -- The BLA (Biologics License Application) for the "HPC-Cord Blood" product, was submitted to FDA on January 7th, 2022, and StemCyte was officially notified on March 8th, 2022, that the submission was acceptable to enter the biologics license quality review process.

Key Points: 
  • The "HPC-Cord Blood" is an umbilical cord blood hematopoietic stem cell product intended for unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system.
  • In the past 20 years, StemCyte has provided more than 2,200 cord blood units for transplantation to 1 in 20 patients worldwide who receive umbilical cord blood transplants.
  • StemCyte is a regenerative cell therapy company that is developing cell therapy pipeline products as well as providing both public and private umbilical cord blood banking services.
  • StemCyte considers umbilical cord blood banking its core competence, while actively pursuing new regenerative cell therapy indications.

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

Retrieved on: 
Wednesday, February 2, 2022
CNS, Medical Center, Principal, Part, Forward-looking statement, ADHD, Patient, NASDAQ, University, University of California, San Francisco, Trial of the century, SEC, UCSF, Distribution, Cedars-Sinai Medical Center, Technology, US, Part Two, Attention deficit hyperactivity disorder, Population, CAGR, Hospital, Stimulant, Taipei Veterans General Hospital, U.S. Securities and Exchange Commission, Demography, Company, Risk, Stanford University, GLOBE, ITT, Ophthalmology, Phase, Drug development, San Francisco, Comment, National Taiwan University Hospital, Security (finance), CA, Pharmaceutical industry, Adult

Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022.

Key Points: 
  • Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022.
  • This randomized, double-blind, placebo-controlled Part 2 study involves a total of approximately 100 patients from the United States and Taiwan.
  • The results from the Part 1 study demonstrated the therapeutic value of PDC-1421 and support further clinical development of ABV-1505 for the treatment of ADHD.
  • We expect to have a productive discussion finalizing the Part 2 study protocol on February 14th, said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma.

The Synergy Between AI and Healthcare Explored at 2021 Taiwan Innotech Expo

Retrieved on: 
Tuesday, October 19, 2021
National Taiwan University Hospital, Wilson, AstraZeneca, AWS, Graphics processing unit, Privacy, Area studies, Association, Technology, Hospital, COVID-19, Collection, Precision medicine, Drug development, Genomics, Ministry of Science, Amazon Web Services, Amazon, Ministry, Taipei Veterans General Hospital, Industry, AI, Ministry of Health and Welfare (South Korea), Cancer, Deep learning, Academia Sinica, MRI, Medical device

However, it requires a high degree of integration among various previously unrelated sectors to ensure competence.

Key Points: 
  • However, it requires a high degree of integration among various previously unrelated sectors to ensure competence.
  • According to Wu, it is necessary to find talents with interdisciplinary skills and to overcome the differences in organizational cultures.
  • Wilson To, the head of worldwide healthcare, life sciences and genomics at Amazon Web Services (AWS), also participated in the Expo, and shared Amazon's experiences in smart healthcare.
  • At the Innotech Expo, Nvidia's global head of medical AI, Mona Flores, indicated that Nvidia had leveraged deep learning to come up with customized data processing and analytics for medical AI applications.

IMPACT Therapeutics Appoints Dr. Chun-Pyn Shen as Head of Regulatory Affairs

Retrieved on: 
Thursday, September 30, 2021
Patent, Therapy, DDR, Molecular biology, Avelumab, College of Medicine, University of Pennsylvania, School, Head, Dental school, DNA, Multimedia, Merck & Co., Regulatory affairs, NMPA, Council for Scientific Policy, San Francisco, Prostate cancer, CEO, Squamous cell carcinoma, Parpi, Merck, University, Ovarian cancer, Genetics, Medical school, National Taiwan University, National Taiwan University Hospital, DDS, IND, University of California, San Francisco, R, Neuroscience, RA, Doctor of Philosophy, IMPACT, Industry, PARP, Department, Medical device, Pharmaceutical industry

SHANGHAI, Sept. 30, 2021 /PRNewswire/ -- IMPACT Therapeutics announced that Dr. Chun-Pyn Shen was appointed as Head of Regulatory Affairs (Vice President).

Key Points: 
  • SHANGHAI, Sept. 30, 2021 /PRNewswire/ -- IMPACT Therapeutics announced that Dr. Chun-Pyn Shen was appointed as Head of Regulatory Affairs (Vice President).
  • Reporting to CEO directly, Dr Shen will lead the Department of Regulatory Affairs which is responsible for the formulation and execution of global regulatory strategy for all IMPACT pipeline products.
  • "I am thrilled to join IMPACT Therapeutics as Head of Regulatory Affairs.
  • IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality.